Here are the DEF 14A proxy statements from Vivos Therapeutics, Inc. (VVOS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow VVOS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VVOS filings page.
Vivos Therapeutics, Inc. is asking stockholders to vote at a virtual annual meeting on December 2, 2026, on seven director nominees and nine other proposals. The agenda includes a proposed reverse split in a range of 1-for-20 to 1-for-40; approval for issuance of up to 18,476,959 common shares upon conversion or exercise of Series A securities held by New Seneca Partners Inc. and affiliates; and approval for issuance of up to 80,000,000 common shares upon conversion of Series C preferred stock issued to SOD Sciences, Inc. The Board would set the reverse-split ratio and timing and may abandon the amendment.
Other proposals would increase the 2024 equity plan’s authorized shares by 4,900,000, from 4,100,000 to 9,000,000, and convert the company from Delaware to Nevada. The Board recommends votes for each nominee and Proposals 2 and 4–10, and a three-year interval for future executive-compensation votes.
On June 5, 2026, Nasdaq notified Vivos that it no longer met the $1.00 minimum bid-price requirement; the initial compliance period runs to December 2, 2026. On October 20, 2026, Nasdaq staff notified Vivos that it had regained compliance with the separate stockholders’ equity requirement, subject to evidence in its next periodic report.